| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/14/2013 | US8440181 Prevention of micronutrient deficiencies associated with common disabilities in the over 50 adult |
| 05/14/2013 | CA2687377C Immunoglobulin fusion proteins |
| 05/14/2013 | CA2555463C Inhibitors of tgf-r signaling for treatment of cns disorders |
| 05/14/2013 | CA2548202C Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 05/14/2013 | CA2521217C Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| 05/14/2013 | CA2509827C A set of oligo-nucleotides against hiv infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 05/14/2013 | CA2506647C Method for digesting proteins highly resistant to denaturation and degradation |
| 05/14/2013 | CA2477878C Peptides selectively lethal to malignant and transformed mammalian cells |
| 05/14/2013 | CA2441562C Short bioactive peptides and methods for their use |
| 05/14/2013 | CA2434303C Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 05/14/2013 | CA2419469C Derivatives of peptides and peptide mimetics having integrin inhibitor properties ii |
| 05/14/2013 | CA2389487C Process for the production of a reversibly inactive acidified plasmin composition |
| 05/14/2013 | CA2376698C Streptogramin derivatives, preparation and compositions containing them |
| 05/14/2013 | CA2263890C Recombinant vascular endothelial cell growth factor d (vegf-d) |
| 05/14/2013 | CA2242342C Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 05/10/2013 | WO2013067530A2 Virion derived protein nanoparticles for delivering radioisotopes for the diagnosis and treatment of malignant and systemic disease and the monitoring of therapy |
| 05/10/2013 | WO2013067420A1 Acth for treatment of kidney disease |
| 05/10/2013 | WO2013067357A1 Peptide analogs for treating diseases and disorders |
| 05/10/2013 | WO2013067322A1 Method for determination of pharmacological properties of recombinant proteins |
| 05/10/2013 | WO2013067309A1 Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| 05/10/2013 | WO2013067198A1 Gene signature for the prediction of nf-kappab activity |
| 05/10/2013 | WO2013067195A1 Methods and compositions for wound treatment |
| 05/10/2013 | WO2013067022A1 Formulations for the treatment of diabetes |
| 05/10/2013 | WO2013066795A1 Stable pharmaceutical formulations of growth factor peptides |
| 05/10/2013 | WO2013066374A2 Humanin protection of dopaminergic neurons |
| 05/10/2013 | WO2013066274A1 Self-assembled composite ultrasmall peptide-polymer hydrogels |
| 05/10/2013 | WO2013066047A1 Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker |
| 05/10/2013 | WO2013065913A1 Gene therapy for diabetic neuropathy using an hgf isoform |
| 05/10/2013 | WO2013065690A1 Prophylactic or therapeutic agent for virus infectious disease |
| 05/10/2013 | WO2013065078A2 Topical preparation containing ngf for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo |
| 05/10/2013 | WO2013065017A2 Platelet rich plasma (prp) and prominin-1 derived peptide stimulate lymphangiogenesis |
| 05/10/2013 | WO2013064787A1 Quick-acting insulin formulation including an oligosaccharide |
| 05/10/2013 | WO2013064585A1 Treatment of musculoskeletal fibroproliferative disorders |
| 05/10/2013 | WO2013064583A1 Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| 05/10/2013 | WO2013064508A1 Polyethylene glycol based prodrug of adrenomedullin and use thereof |
| 05/10/2013 | WO2013064244A1 S100 family proteins and their uses |
| 05/10/2013 | WO2013063928A1 Small peptide for resisting thrombus and platelet aggregation |
| 05/10/2013 | WO2013063877A1 Glp-1 derivate dlg3312 and solid-phase chemical synthesis method thereof |
| 05/10/2013 | WO2013063755A1 Oligopeptide for treating liver fibrosis and/or hepatitis b and/or improving liver function |
| 05/10/2013 | WO2013063695A1 Compositions and methods for preventing and treating oral diseases |
| 05/10/2013 | WO2013063692A1 Inhibition of collagen synthesis |
| 05/10/2013 | WO2013040341A3 Wnt7a compositions and methods of using the same |
| 05/10/2013 | WO2013040309A3 Wnt compositions and therapeutic uses of such compositions |
| 05/10/2013 | WO2013036827A3 Fungal-specific metalloproteases and uses thereof |
| 05/10/2013 | WO2013032828A3 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| 05/10/2013 | WO2013032210A3 Biomembrane permeable composition |
| 05/10/2013 | WO2013028555A3 Methods for weight loss and ketogenic compositions |
| 05/10/2013 | WO2013025538A3 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
| 05/10/2013 | WO2013018098A3 Long-acting growth hormone and methods of producing same |
| 05/10/2013 | WO2013016578A3 Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers |
| 05/10/2013 | WO2013006449A3 Anti-properdin antibodies and uses thereof |
| 05/10/2013 | WO2012178022A3 Therapeutic applications targeting sarm1 |
| 05/10/2013 | WO2012171983A3 Method for the production of a polymerized product |
| 05/10/2013 | WO2012161545A9 Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna |
| 05/10/2013 | WO2010125566A3 Markers for cancer detection |
| 05/10/2013 | CA2854271A1 Topical preparation containing ngf for inducing skin pigmentation and for the treatment of cutaneous dyschromias and vitiligo |
| 05/10/2013 | CA2854202A1 Inhibition of collagen synthesis |
| 05/10/2013 | CA2854175A1 Peptide analogs for treating diseases and disorders |
| 05/10/2013 | CA2854160A1 Methods and compositions for wound treatment |
| 05/10/2013 | CA2854134A1 Polyethylene glycol based prodrug of adrenomedullin and use thereof |
| 05/10/2013 | CA2854129A1 Compositions useful for the treatment of viral diseases |
| 05/10/2013 | CA2853942A1 Formulations for the treatment of diabetes |
| 05/10/2013 | CA2853918A1 Gene therapy for diabetic neuropathy using an hgf isoform |
| 05/10/2013 | CA2853857A1 Compositions and methods for preventing and treating oral diseases |
| 05/10/2013 | CA2853829A1 Evaluation and improvement of nuclease cleavage specificity |
| 05/10/2013 | CA2853671A1 Medical use |
| 05/09/2013 | US20130117871 Human Antibodies Derived from Immunized Xenomice |
| 05/09/2013 | US20130116311 Catecholamine enzyme fusions |
| 05/09/2013 | US20130116309 Oligomeric compounds for the modulation of hif-1a expression |
| 05/09/2013 | US20130116307 Novel cyclic cationic lipids and methods of use |
| 05/09/2013 | US20130116305 Methods and compositions for the inhibition of hiv-1 replication |
| 05/09/2013 | US20130116299 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
| 05/09/2013 | US20130116290 Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals |
| 05/09/2013 | US20130116268 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 05/09/2013 | US20130116200 Treatment of Vascular Complications of Diabetes |
| 05/09/2013 | US20130116196 Muscle fatigue substance cytokines and methods of inhibiting tumor growth therewith |
| 05/09/2013 | US20130116195 Binding ligand linked drug delivery conjugates of tubulysins |
| 05/09/2013 | US20130116193 Use of the pat nonapeptide in treating and preventing neurodegenerative diseases |
| 05/09/2013 | US20130116192 N-(aminoacyl)-amino compound |
| 05/09/2013 | US20130116190 Hyaluronic acid-collagen matrices for tissue engineering |
| 05/09/2013 | US20130116187 Artificial cartilage and its production method |
| 05/09/2013 | US20130116186 Lubricin injections to maintain cartilage health |
| 05/09/2013 | US20130116183 Peptides that inhibit angiotensin converting enzyme and peptides with antioxidant activity purified from ovotransferrin and methods of producing and using the same |
| 05/09/2013 | US20130116182 Factor VIII B Cell Epitope Variants Having Reduced Immunogenicity |
| 05/09/2013 | US20130116181 Method of treating dyspnea associated with acute heart failure |
| 05/09/2013 | US20130116180 Parathyroid hormone analogs and uses thereof |
| 05/09/2013 | US20130116179 Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| 05/09/2013 | US20130116178 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
| 05/09/2013 | US20130116177 Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
| 05/09/2013 | US20130116175 Reversible pegylated drugs |
| 05/09/2013 | US20130116174 Compositions and methods for increasing poultry hatchability and early performance |
| 05/09/2013 | US20130116171 Methods for treating metabolic disorders using fgf |
| 05/09/2013 | US20130116169 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 05/09/2013 | US20130115682 Fusion proteins |
| 05/09/2013 | US20130115620 Novel Hemopoietin Receptor Protein, NR10 |
| 05/09/2013 | US20130115602 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
| 05/09/2013 | US20130115589 Pharmaceutical Composition for Treatment and Prevention of Herpes Virus Infections |
| 05/09/2013 | US20130115302 Polysaccharide micro-particle encapsulatin growth factor |
| 05/09/2013 | US20130115278 Peptide Epitopes of Apolipoprotein B |
| 05/09/2013 | US20130115277 Peptide Epitopes of Apolipoprotein B |